Adverum Biotechnologies (ADVM) Stock Statistics & Valuation Metrics

Adverum Biotechnologies has a market cap or net worth of $69.27M. The enterprise value is $66.57M.

Adverum Biotechnologies has 20.80M shares outstanding. The number of shares has decreased by -2.65% in one year.

Adverum Biotechnologies’s return on equity (ROE) is -1.40 and return on invested capital (ROIC) is -77.51%.

The current PE Ratio of Adverum Biotechnologies is -0.65. Adverum Biotechnologies’s PEG ratio is 0.03.

In the last 12 months, Adverum Biotechnologies had revenue of -$2.60M and earned -$94.11M in profits. Earnings per share was -$6.03.

In the last 12 months, operating cash flow was -$85.62M and capital expenditures -$519.00K, giving a free cash flow of -$86.14M billion.

Adverum Biotechnologies pays an annual dividend of , resulting in a dividend yield of

Adverum Biotechnologies upcoming earnings date is May 8, 2025, TBA.

Adverum Biotechnologies as a current ratio of 4.13, with Debt / Equity ratio of 0.90

In the past 12 months, Adverum Biotechnologies has paid -$179.28K in taxes.

Adverum Biotechnologies EV to EBITDA ratio is -0.64, with an EV/FCF ratio of -0.83.

Adverum Biotechnologies has $153.24M in cash and marketable securities with $73.26M in debt, giving a net cash position of -$79.98M billion.

Gross margin is -56.78%, with operating margin of -3444.19%, and net profit margin of -3254.58%.

The average price target for Adverum Biotechnologies is $30.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy